Induced Pluripotent Stem Cells in Disease Modelling and Drug Discovery

Overview

Journal Nat Rev Genet

Specialty Genetics

Date 2019 Feb 10

PMID 30737492

Citations 263

Authors

R Grant Rowe

George Q Daley

Affiliations

Soon will be listed here.

Abstract

The derivation of induced pluripotent stem cells (iPSCs) over a decade ago sparked widespread enthusiasm for the development of new models of human disease, enhanced platforms for drug discovery and more widespread use of autologous cell-based therapy. Early studies using directed differentiation of iPSCs frequently uncovered cell-level phenotypes in monogenic diseases, but translation to tissue-level and organ-level diseases has required development of more complex, 3D, multicellular systems. Organoids and human-rodent chimaeras more accurately mirror the diverse cellular ecosystems of complex tissues and are being applied to iPSC disease models to recapitulate the pathobiology of a broad spectrum of human maladies, including infectious diseases, genetic disorders and cancer.

Citing Articles

Novel CRISPR-Cas9 iPSC knockouts for PCCA and PCCB genes: advancing propionic acidemia research.

Garcia-Tenorio E, Alvarez M, Gallego-Bonhomme M, Desviat L, Richard E Hum Cell. 2025; 38(3):64.

PMID: 40044943 PMC: 11882705. DOI: 10.1007/s13577-025-01193-z.

Sustaining Brain Youth by Neural Stem Cells: Physiological and Therapeutic Perspectives.

Santos M, Moreira J, Santos S, Sola S Mol Neurobiol. 2025; .

PMID: 39985708 DOI: 10.1007/s12035-025-04774-z.

MorPhiC Consortium: towards functional characterization of all human genes.

Adli M, Przybyla L, Burdett T, Burridge P, Cacheiro P, Chang H Nature. 2025; 638(8050):351-359.

PMID: 39939790 DOI: 10.1038/s41586-024-08243-w.

Generation and maintenance of kidney and kidney cancer organoids from patient-derived material for drug development and precision oncology.

Gubala J, Mieville V, Benamran D, Tille J, Valerio M, Nowak-Sliwinska P Mol Ther Methods Clin Dev. 2024; 32(4):101368.

PMID: 39659758 PMC: 11629258. DOI: 10.1016/j.omtm.2024.101368.

Advancing Pain Understanding and Drug Discovery: Insights from Preclinical Models and Recent Research Findings.

Asiri Y, Moni S, Ramar M, Chidambaram K Pharmaceuticals (Basel). 2024; 17(11).

PMID: 39598351 PMC: 11597627. DOI: 10.3390/ph17111439.

References

Park I, Zhao R, West J, Yabuuchi A, Huo H, Ince T . Reprogramming of human somatic cells to pluripotency with defined factors. Nature. 2007; 451(7175):141-6. DOI: 10.1038/nature06534. View

Yu J, Vodyanik M, Smuga-Otto K, Antosiewicz-Bourget J, Frane J, Tian S . Induced pluripotent stem cell lines derived from human somatic cells. Science. 2007; 318(5858):1917-20. DOI: 10.1126/science.1151526. View

Thomson J, Itskovitz-Eldor J, Shapiro S, Waknitz M, Swiergiel J, Marshall V . Embryonic stem cell lines derived from human blastocysts. Science. 1998; 282(5391):1145-7. DOI: 10.1126/science.282.5391.1145. View

Zhang S, Wernig M, Duncan I, Brustle O, Thomson J . In vitro differentiation of transplantable neural precursors from human embryonic stem cells. Nat Biotechnol. 2001; 19(12):1129-33. DOI: 10.1038/nbt1201-1129. View

Reubinoff B, Itsykson P, Turetsky T, Pera M, Reinhartz E, Itzik A . Neural progenitors from human embryonic stem cells. Nat Biotechnol. 2001; 19(12):1134-40. DOI: 10.1038/nbt1201-1134. View

He J, Ma Y, Lee Y, Thomson J, Kamp T . Human embryonic stem cells develop into multiple types of cardiac myocytes: action potential characterization. Circ Res. 2003; 93(1):32-9. DOI: 10.1161/01.RES.0000080317.92718.99. View

Assady S, Maor G, Amit M, Itskovitz-Eldor J, Skorecki K, Tzukerman M . Insulin production by human embryonic stem cells. Diabetes. 2001; 50(8):1691-7. DOI: 10.2337/diabetes.50.8.1691. View

Kaufman D, Hanson E, LEWIS R, Auerbach R, Thomson J . Hematopoietic colony-forming cells derived from human embryonic stem cells. Proc Natl Acad Sci U S A. 2001; 98(19):10716-21. PMC: 58532. DOI: 10.1073/pnas.191362598. View

Chadwick K, Wang L, Li L, Menendez P, Murdoch B, Rouleau A . Cytokines and BMP-4 promote hematopoietic differentiation of human embryonic stem cells. Blood. 2003; 102(3):906-15. DOI: 10.1182/blood-2003-03-0832. View

10.

Eiges R, Urbach A, Malcov M, Frumkin T, Schwartz T, Amit A . Developmental study of fragile X syndrome using human embryonic stem cells derived from preimplantation genetically diagnosed embryos. Cell Stem Cell. 2008; 1(5):568-77. DOI: 10.1016/j.stem.2007.09.001. View

11.

Tulpule A, Lensch M, Miller J, Austin K, DAndrea A, Schlaeger T . Knockdown of Fanconi anemia genes in human embryonic stem cells reveals early developmental defects in the hematopoietic lineage. Blood. 2010; 115(17):3453-62. PMC: 2867260. DOI: 10.1182/blood-2009-10-246694. View

12.

Urbach A, Schuldiner M, Benvenisty N . Modeling for Lesch-Nyhan disease by gene targeting in human embryonic stem cells. Stem Cells. 2004; 22(4):635-41. DOI: 10.1634/stemcells.22-4-635. View

13.

Ebert A, Yu J, Rose Jr F, Mattis V, Lorson C, Thomson J . Induced pluripotent stem cells from a spinal muscular atrophy patient. Nature. 2008; 457(7227):277-80. PMC: 2659408. DOI: 10.1038/nature07677. View

14.

Moretti A, Bellin M, Welling A, Jung C, Lam J, Bott-Flugel L . Patient-specific induced pluripotent stem-cell models for long-QT syndrome. N Engl J Med. 2010; 363(15):1397-409. DOI: 10.1056/NEJMoa0908679. View

15.

Park I, Arora N, Huo H, Maherali N, Ahfeldt T, Shimamura A . Disease-specific induced pluripotent stem cells. Cell. 2008; 134(5):877-86. PMC: 2633781. DOI: 10.1016/j.cell.2008.07.041. View

16.

Maehr R, Chen S, Snitow M, Ludwig T, Yagasaki L, Goland R . Generation of pluripotent stem cells from patients with type 1 diabetes. Proc Natl Acad Sci U S A. 2009; 106(37):15768-73. PMC: 2735559. DOI: 10.1073/pnas.0906894106. View

17.

Brennand K, Simone A, Jou J, Gelboin-Burkhart C, Tran N, Sangar S . Modelling schizophrenia using human induced pluripotent stem cells. Nature. 2011; 473(7346):221-5. PMC: 3392969. DOI: 10.1038/nature09915. View

18.

Lee G, Papapetrou E, Kim H, Chambers S, Tomishima M, Fasano C . Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs. Nature. 2009; 461(7262):402-6. PMC: 2784695. DOI: 10.1038/nature08320. View

19.

Liu G, Suzuki K, Li M, Qu J, Montserrat N, Tarantino C . Modelling Fanconi anemia pathogenesis and therapeutics using integration-free patient-derived iPSCs. Nat Commun. 2014; 5:4330. PMC: 4291073. DOI: 10.1038/ncomms5330. View

20.

Robinton D, Daley G . The promise of induced pluripotent stem cells in research and therapy. Nature. 2012; 481(7381):295-305. PMC: 3652331. DOI: 10.1038/nature10761. View